Bajaj Healthcare Q2 FY26 – From Opium to APIs: 49% Profit Jump, CFOs Vanishing, and 9 Factories Running Like Exam Centers on Viva Day
1. At a Glance
Welcome to the pharmaceutical circus where APIs meet dopamine and CFOs exit faster than your New Year resolutions. Bajaj Healthcare Ltd (BHL), the ₹1,483-crore small-cap from Maharashtra and Gujarat, just dropped a Q2 FY26 showstopper — Revenue ₹148.0 crore, PAT ₹12.4 crore, and a YoY profit surge of 49.3%.
The stock sits at ₹470, down ~9.6% in 3 months (because small-caps love emotional roller-coasters), but still up 22.8% in the past year. With a P/E of 29x, ROE 10.7%, and ROCE 11.4%, it’s not the kind of chemistry you brag about on Tinder, but hey — it works.
Oh, and did we mention? Bajaj Healthcare makes everything from amino acids to poppy-derived alkaloids — yes, the government literally trusted them with Opium Gum. Your next cough syrup could have a little Bajaj in it.
So, let’s audit this biochemical soap opera — one molecule at a time.
2. Introduction – Where Pharma Meets Bollywood
Imagine if Walter White was born in Thane. That’s Bajaj Healthcare for you. Founded in 1993, it started as a humble maker of pharmaceutical ingredients, but over three decades has evolved into a globe-trotting exporter of APIs, nutraceuticals, and fine chemicals — shipping drugs to 62+ countries.
From Sun Pharma to HUL, the company’s clientele list reads like a who’s-who of Indian pharma’s elite. Yet, behind that glossy facade, BHL’s quarterly dance looks like an episode of Kaun Banega CFO? — with resignations, promotions, and “monitoring agency reports” that could make auditors blush.
And just when you think things will stabilize, they drop a headline like:
“Bajaj Healthcare receives Phase III nods for Suvorexant and Cenobamate.”
Because why just make paracetamol when you can aim for insomnia and epilepsy markets?
So, buckle up. We’re about to decode a company that makes Chlorhexidine, Ascorbic Acid, and occasional headlines for government opium permissions — truly India’s most unpredictable chemistry lab.
3. Business Model – WTF Do They Even Do?
Bajaj Healthcare is basically the Swiss Army knife of the pharma world — they make everything except vaccines and excuses.
Their model runs on three verticals:
Intermediates: The behind-the-scenes chemicals that make the actual drugs work. Think of it as the “sambar powder” of pharma — no one praises it, but you can’t cook without it.
Active Pharmaceutical Ingredients (APIs): The main compounds that treat your headache, your insomnia, and your portfolio anxiety.
Finished Dosage Formulations (FDFs): The final tablets, capsules, and powders. Because someone has to put the science into a bottle.
They operate 9 units across Maharashtra and Gujarat, collectively capable of producing 730 MT of APIs/month and 92 million tablets per month.
Their products range from amino acids to neurological drugs — and recently, they got a once-in-a-generation license to process Opium Gum. Yes, the kind that usually comes with a narcotics disclaimer.
Exports make up ~66% of revenue, meaning most of their profits come in dollars, but most of their headaches come in rupees.
4. Financials Overview
Source table
Metric
Latest Qtr (Q2 FY26)
YoY Qtr (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue (₹ Cr)
148.0
133.0
149.0
+11.1%
-0.7%
EBITDA (₹ Cr)
27.0
18.0
25.0
+50.0%
+8.0%
PAT (₹ Cr)
12.4
8.3
12.0
+49.3%
+3.3%
EPS (₹)
3.52
2.35
3.45
+49.8%
+2.0%
Commentary: EBITDA margin stands near 18%, meaning they earn more on drugs than most IT folks do on overtime. Profit growth of 49% YoY — not bad for a company whose debtors take 169 days to pay.
5. Valuation Discussion – The Fair Value Range
We ran three valuation models:
(a) P/E Method: Annualized EPS = ₹3.52 × 4 = ₹14.08 Industry P/E = ~32.8× Fair value range = ₹14.08 × (22× to 30×) = ₹310 – ₹425
